Upcoming Milestones: A dose escalation update is expected from the Phase 1/2 clinical trial of TNG908 in patients with MTAP-deleted solid tumors during the first half of 2023. The initiation of the Phase 1/2 clinical trial for TNG462, a next-generation MTA-cooperative PRMT5 inhibitor, is expected in mid-2023. The IND filing for TNG260, a first-in-class CoREST inhibitor, is on track for the first half of 2023. The IND filing for TNG348, a novel USP1 inhibitor that is being developed for treatment of BRCA1 and BRCA2-mutant cancers, is on track for mid-2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNGX:
